Professional Documents
Culture Documents
DOI 10.1007/s00134-015-3701-9
Marc Leone
Sharon Einav
Introduction
In 2013, the British period drama television series
Downton Abbey portrayed the death of Lady Sybil
Branson from postpartum eclampsia, raising public
awareness to signs of preeclampsia and instigating debate
regarding the potentially lethal outcome of hypertensive
disease of pregnancy. Obstetrical complications constitute
0.15 % of hospital deliveries and 1.84 % of intensive care
unit (ICU) admissions. Peripartum hemorrhage, the most
prevalent cause of maternal death, has a 55 % causespecific mortality [1]. Early identification of hemorrhage,
definitive surgery, transcatheter arterial embolization and
correction of coagulopathy are the mainstays of treatment.
Hypertensive diseases constitute the second most prevalent cause of maternal death worldwide [2], and are
responsible for 3666 % of ICU admissions and 10 % of
maternal deaths in Europe [3]. Women admitted to ICU
The four hypertensive disorders of pregnancy include preexisting (chronic) hypertension, gestational hypertension,
preeclampsia and eclampsia (Table 1). Diagnosis requires
two separate measurements of a systolic blood pressure
C140 mmHg and/or a diastolic blood pressure
C90 mmHg in the same arm [5]. Preeclampsia is confirmed when [300 mg protein is also detected in 24 h
urine collection. Preeclampsia is reported in 28 % of
pregnancies. It is associated with an eight-times higher
frequency of maternal near-miss than in pregnancies
without this condition [6]. Malignant hypertension is defined when maternal hypertension is associated with
ischemic organ damage [7].
Preeclampsia has been associated with several cardiovascular diseases. Current knowledge establishes the
presence of shared risk factors rather than a causative relationship. Preeclampsia is attributable to a disparity
between uteroplacental supply and fetal demands, leading
to both maternal and fetal systemic manifestations of inflammation. Severe preeclampsia, defined as preeclampsia
accompanied by at least one severe complication, is responsible for 38 % of maternal deaths among obstetrical
ICU admissions [3].
HELLP syndrome and thrombotic thrombocytopenic
purpura (TTP) are often confounded with preeclampsia.
The hallmarks of HELLP are microangiopathic hemolysis
(schistocytes in peripheral blood smear and elevated
indirect plasma bilirubin), elevated liver enzymes and a
platelet count below 100,000 mm3. Conversely, HELLP
syndrome may be accompanied by only mild elevations in
blood pressure. Up to 20 % of the cases have no
Pre-existing
hypertension
Gestational
hypertension
Preeclampsia
Eclampsia
New proteinuria, or
One/more adverse condition(s) or
One/more severe complication(s)
Severe preeclampsia: preeclampsia with one or
Cardiovascular and fluid management
more severe complications
New onset of grand mal seizure activity and/or
unexplained coma during pregnancy, intraGestational age, stage of labor, disease severity, conpartum or in the early post-partum period
comitant comorbidities and medications may all affect the
Evidence-based management
Interventions reducing maternal mortality from hypertensive diseases of pregnancy include routine calcium
supplementation, antiplatelet agents in women at risk of
preeclampsia, magnesium sulphate (MgSO4) for treatment of preeclampsia and eclampsia, antihypertensive
drugs for the treatment of mild to moderate hypertension
[11] and adherence to established guidelines [12]. Despite
measurable reductions in the rate of suboptimal care,
inadequate management is still reported in 70 % of maternal deaths due to hypertensive disorders, and 50 % of
these are avoidable [3]. Prevention of systolic hypertension and bridging support for failing organs are treatment
priorities. Systolic arterial hypertension is the most important predictor of stroke in preeclampsia. First line
therapy is either intravenous labetalol and oral nifedipine
or intravenous nicardipine. High dose diazoxide and
sodium nitropusside are recommended for refractory hypertension in the ICU [5]. Hydralazine is no longer
considered first line treatment and MgSO4 should not be
used as an antihypertensive [5].
Management of delivery
Women with preeclampsia can be expectantly managed
up to a gestational age of 34 weeks but should be delivered at term [5]. Manifestations of organ failure should
prompt delivery regardless of gestational age. Vaginal
delivery is acceptable and cervical ripening should be
undertaken if conditions are unfavorable [5]. The third
stage of labor should be actively managed with oxytocin
[5]. Early insertion of an epidural catheter is recommended for labor pain control if there is no
contraindication to neuraxial anesthesia [5]. As they are at
increased risk for difficult airway management, spinal
anesthesia is recommended for cesarean delivery. The
decrease in blood pressure induced by spinal anesthesia in
preeclamptic parturients is less severe than that observed
in healthy parturients [18]. Reversal of the effects of
neuraxial anesthesia may be accompanied by decreased
stroke volume and cardiac output. If general anesthesia is
required, remifentanil at 1.34 lg/kg attenuates the hypertensive response to tracheal intubation [19].
Summary
Preeclampsia remains an important cause of avoidable
maternal morbidity and mortality. Publication of guidelines and monitoring adherence to life-saving therapies
should be prioritized. Prediction of fluid responsiveness
requires individual hemodynamic investigation. Future
studies are required to determine the optimal early
warning system and monitoring tools for providing early
and non-invasive hemodynamic assessment.
Conflicts of interest The authors have no conflict of interest to
disclose in relation with this topic.
References
6. Abalos E, Cuesta C, Carroli G, Qureshi
1. Mhyre JM, Tsen LC, Einav S, Kuklina
Z, Widmer M, Vogel JP, Souza JP,
EV, Leffert LR, Bateman BT (2014)
WHO Multicountry Survey on Maternal
Cardiac arrest during hospitalization for
and Newborn Health Research Network
delivery in the United States,
(2014) Pre-eclampsia, eclampsia and
19982011. Anesthesiology
adverse maternal and perinatal
120:810818
,
outcomes: a secondary analysis of the
2. Say L, Chou D, Gemmill A, Tuncalp O
World Health Organization
Moller AB, Daniels J, Gulmezoglu AM,
Multicountry Survey on Maternal and
Temmerman M, Alkema L (2014)
Newborn Health. BJOG 121(Suppl
Global causes of maternal death: a
1):1424
WHO systematic analysis. Lancet Glob
7. Taylor J (2013) 2013 ESH/ESC
Health 2:e323e333
guidelines for the management of
3. Saucedo M, Deneux-Tharaux C,
arterial hypertension. Eur Heart J
Bouvier-Colle MH, French National
34:21082109
Experts Committee on Maternal
8. Moussa HN, Arian SE, Sibai BM
Mortality (2013) Ten years of
(2014) Management of hypertensive
confidential inquiries into maternal
disorders in pregnancy. Womens Health
deaths in France, 19982007. Obstet
(Lond Engl) 10:385404
Gynecol 122:752760
9. Haram K, Mortensen JH, Nagy B
4. Gillon TE, Pels A, von Dadelszen P,
(2014) Genetic aspects of preeclampsia
MacDonell K, Magee LA (2014)
and the HELLP syndrome. J Pregnancy
Hypertensive disorders of pregnancy: a
2014:910751
systematic review of international
clinical practice guidelines. PLoS ONE 10. Mannucci PM (2015) Understanding
organ dysfunction in thrombotic
9:e113715
thrombocytopenic purpura. Intensive
5. Magee LA, Pels A, Helewa M, Rey E,
Care Med [Epub ahead of print]
von Dadelszen P, Canadian
11. Ronsmans C, Campbell O (2011)
Hypertensive Disorders of Pregnancy
Quantifying the fall in mortality
Working Group (2014) Diagnosis,
associated with interventions related to
evaluation, and management of the
hypertensive diseases of pregnancy.
hypertensive disorders of pregnancy:
BMC Public Health 11(Suppl 3):S8
executive summary. J Obstet Gynaecol
12. Schaap TP, Knight M, Zwart JJ,
Can 36:416441
Kurinczuk JJ, Brocklehurst P, van
Roosmalen J, Bloemenkamp KW
(2014) Eclampsia, a comparison within
the International Network of Obstetric
Survey Systems. BJOG 121:15211528